Association between annual hemoglobin variability and thromboembolism risk in patients on hemodialysis: a retrospective cohort study in Japan
Authors:
- Naoki ChigusaNCNaoki Chigusa
- Kiyotaka UchiyamaKiyotaka Uchiyama
- Keigo ShibagakiKSKeigo Shibagaki
- Akane YanaiAYAkane Yanai
- Kenta KandaKKKenta Kanda
- Jun ItoJIJun Ito
- Naoki WashidaNWNaoki Washida
Open Access
- 18 March 2026
- journal article
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 12 (1)
Abstract
Background: Hemoglobin levels fluctuate in patients on hemodialysis, and a rapid increase in hemoglobin may trigger thromboembolism. However, the association between annual variability in hemoglobin levels and thromboembolism in patients on hemodialysis remains unclear. Methods: This multicenter, retrospective cohort study included 307 patients (202 males) who underwent continuous hemodialysis at one of the three Shibagaki Clinics (Jiyugaoka, Togoshi, and Kugahara) from April 2019 to March 2020. The mean age was 70.0 ± 12.5 years, and the median hemodialysis duration was 5.1 years. Annual hemoglobin variability was defined as the standard deviation of hemoglobin levels, calculated from monthly predialysis hemoglobin values over a 1-year period. During the observation period from April 2020 to March 2023, the primary outcome was the association between hemoglobin variability and the incidence of thromboembolism (acute coronary syndrome, cerebral infarction, and vascular access thrombosis), and the secondary outcomes were major adverse cardiovascular events (MACEs) and all-cause hospitalization, evaluated using the Cox regression analysis. Results: The mean annual hemoglobin variability was 0.76 ± 0.32 g/dL. Patients were classified into three groups on the basis of hemoglobin standard deviation tertiles. By log-rank test, the patients with high hemoglobin variability had significantly lower rates of thromboembolism-free survival ( P < 0.001) and all-cause hospitalization-free survival ( P = 0.034), compared with those with low hemoglobin variability. By Cox regression analysis adjusted for age, sex, hemodialysis duration, comorbidities, mean annual hemoglobin level, and other dialysis-related parameters, greater hemoglobin variability was significantly associated with a higher risk of thromboembolism (hazard ratio [HR], 3.84; 95% confidence interval [CI], 2.03–7.28, P < 0.001), MACEs (HR, 1.92; 95% CI 1.02–3.61; P = 0.044), and all-cause hospitalization (HR, 1.64; 95% CI 1.08–2.50; P = 0.022). Sensitivity analysis using the subdistribution hazard model yielded results similar to those observed for the primary outcome (subdistribution HR, 4.70; 95% CI 2.50–8.83; P < 0.001). Conclusions: In Japanese patients on hemodialysis, a greater mean annual hemoglobin variability was associated with thromboembolism, MACEs, and all-cause hospitalization. Further studies are warranted to investigate whether reducing annual hemoglobin variability can aid in mitigating thromboembolic events in patients on hemodialysis.Keywords
This publication has 31 references indexed in Scilit:
- Evaluation of factors underlying differences in venous thromboembolism rates between Black and White patientsJournal of Vascular Surgery: Venous and Lymphatic Disorders, 2025
- Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 TrialsAdvances in Therapy, 2024
- Infectious Risk and Variability of Hemoglobin Level in Patients Undergoing HemodialysisKidney International Reports, 2023
- Seasonal variation and predictors of intradialytic blood pressure decline: a retrospective cohort studyHypertension Research, 2021
- Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM StudyAdvances in Therapy, 2013
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Hemoglobin Variability and Mortality: Confounding by Disease SeverityAmerican Journal of Kidney Diseases, 2011
- Effect of Amlodipine + Candesartan on Cardiovascular Events in Hypertensive Patients With Coronary Artery Disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study)The American Journal of Cardiology, 2010
- Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysisThe Lancet, 2007
- A tandem cosine algorithm for modeling rhythmic changeEcological Modelling, 2000